Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT)

Saved in:
Bibliographic Details
Title: Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT)
Authors: Atthobari J (AUTHOR), Asselbergs FW (AUTHOR), Boersma C (AUTHOR), de Vries R (AUTHOR), Hillege HL (AUTHOR), van Gilst WH (AUTHOR), Gansevoort RT (AUTHOR), de Jong PE (AUTHOR), de Jong-van den Berg LT (AUTHOR), Postma MJ (AUTHOR), PREVEND IT Study Group (CORPORATE AUTHOR)
Source: Clinical Therapeutics. Mar2006, Vol. 28 Issue 3, p432-444. 13p.
Database: Academic Search Ultimate
Description
ISSN:01492918
DOI:10.1016/j.clinthera.2006.03.012